Publications

LeydenLabs-SM-Feb2024-Publication-021624-v01-2

Scientific Reports — February 15, 2024

A pan-influenza monoclonal antibody neutralizes H5 strains and prophylactically protects through intranasal administration

The ongoing spread of avian flu among animals has increased the urgency of developing products that could prevent infection in the event of an H5N1 pandemic. A new study by Leyden Labs, published in Nature’s Scientific Reports, shows that the CR9114 antibody can protect intranasally at low dosages against H5N1 in vivo.

READ IT HERE →

Journal of Epidemiology — February 04, 2023

SARS‑CoV‑2 elicits non‑sterilizing immunity and evades vaccine‑induced immunity: implications for future vaccination strategies.

A new article from Leyden Labs has been published in the European Journal of Epidemiology, titled "SARS‑CoV‑2 elicits non‑sterilizing immunity and evades vaccine‑induced immunity: implications for future vaccination strategies.”

READ THE ARTICLE →

Frontiers in Virology — November 02, 2022

The influenza hemagglutinin stem antibody CR9114: Evidence for a narrow evolutionary path towards universal protection

Recently, our article entitled “The influenza hemagglutinin stem antibody CR9114: Evidence for a narrow evolutionary path towards universal protection,” appeared in a special issue of Frontiers in Virology on the role of genetic and structural insights of neutralizing antibodies to guide viral vaccine design.

READ THE ARTICLE →

LeydenLabs-Social-Publication-011923-v01

Infectious Diseases & Therapy — October 30, 2022

Exploring the Role of Antiviral Nasal Sprays in the Control of Emerging Respiratory Infections in the Community

A new research article by Leyden Labs and partners at Imperial College has been published in Infectious Diseases & Therapy.